6.9 ANTIPLATELET AND VASCULAR EFFECTS OF ASPIRIN IN HEALTHY PERSONS AND PATIENTS WITH TYPE 2 DIABETES

DOI

10.1016/j.artres.2016.10.045How to use a DOI?

Abstract

Background: Treatment with aspirin is a cornerstone in the secondary prevention of cardiovascular disease (CVD) in diabetes, whereas its place in primary prevention remains controversial.

The effect of once-daily aspirin on platelet aggregation is unclear in patients with diabetes. Furthermore, the effects of aspirin on endothelial-dependent vasodilation and arterial stiffness, both important predictors of CVD, needs to be clarified.

Our aim is to investigate both the acute and the chronic effects of aspirin on platelet aggregation, endothelial-dependent vasodilation and arterial stiffness during 24 hours in patients with type 2 diabetes without CVD and in healthy controls.

Method: Based on power calculations, we will include 21 patients with type 2 diabetes and 21 sex and age-matched controls. Platelet aggregation is measured by impedance aggregometry, whereas arterial stiffness (carotid-femoral pulse wave velocity) is assessed by applanation tonometry. Endothelial-dependent vasodilation is assessed by peripheral arterial tonometry.

Outcome variables will be obtained at baseline and 1 hour after administration of aspirin. Participants are then treated for 6 days with once-daily aspirin and measurements are performed again 24 hours and 1 hour after aspirin intake.

Results: Preliminary results will be ready for presentation at the congress.

Perspective: This study provides new insight into whether once-daily dosing of aspirin is sufficient for effective platelet inhibition during 24 hours in patients with type 2 diabetes without CVD. Furthermore, this study will clarify if aspirin has positive effects on endothelial-dependent vasodilatation and arterial stiffness and if these effects are obtained effectively using a standard once-daily regimen of aspirin.

Open Access

This is an open access article distributed under the CC BY-NC license.

TY  - JOUR
AU  - Liv Vernstroem Hald
AU  - Anne-Mette Hvas
AU  - Erik Lerkevang Grove
AU  - Esben Laugesen
AU  - Kristian Loekke Funck
AU  - Per Loegstrup Poulsen
PY  - 2016
DA  - 2016/11/24
TI  - 6.9 ANTIPLATELET AND VASCULAR EFFECTS OF ASPIRIN IN HEALTHY PERSONS AND PATIENTS WITH TYPE 2 DIABETES
JO  - Artery Research
SP  - 61
EP  - 61
VL  - 16
IS  - C
SN  - 1876-4401
UR  - https://doi.org/10.1016/j.artres.2016.10.045
DO  - 10.1016/j.artres.2016.10.045
ID  - Hald2016
ER  -